leadf
logo-loader
viewBAE Systems PLC
(
LSE:BA.
)

Is it time to buy BAE Systems shares? This broker thinks so

Jefferies’ number crunchers said that if BAE is “roughly handled by adverse sentiment, a powerful backstop would be a spin-off of Electronic Systems”, which is worth £10bn

BAE Systems -
The shares are far from tanking, according to the Wall Street broker

BAE Systems PLC (LON:BA.) looks “well set” to weather the downturn in defence spending, says broker Jefferies, which has upgraded its recommendation and target price for the contractor.

The American broker reckons US budgets are likely to be 5% lower 2022 through to 2025 when compared with 2021.

According to its analysts, BAE is “strongly placed” to withstand the headwinds.

They predict underlying earnings (EBIT) will be broadly flat with the with the maker of the Typhoon jet fighter receiving “good fundamental support” from a free cash flow yield of around 7%.

Jefferies’ number crunchers said that if BAE is “roughly handled by adverse sentiment, a powerful backstop would be a spin-off of Electronic Systems”.

The GPS business is estimated to be worth £10bn, or half the company’s enterprise value.

Lifting its target price to 600p a share Jefferies upgraded its recommendation to ‘buy’ from ‘hold’.

The shares, down a fifth from their pre-pandemic peak, were off 1.4% at 524p in afternoon trade.

 

Quick facts: BAE Systems PLC

Follow
LSE:BA.

Price: 559.2 GBX

Market Cap: £17.93 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress. The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate,...

1 hour, 15 minutes ago

2 min read